Get the Stockscreener App
67.04
0.37%
-0.25
After Hours:
67.24
0.20
+0.30%
Dexcom Inc stock is traded at $67.04, with a volume of 4.03M.
It is down -0.37% in the last 24 hours and down -3.32% over the past month.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$67.29
Open:
$67.77
24h Volume:
4.03M
Relative Volume:
0.77
Market Cap:
$26.86B
Revenue:
$3.93B
Net Income/Loss:
$666.90M
P/E Ratio:
73.67
EPS:
0.91
Net Cash Flow:
$665.50M
1W Performance:
-3.82%
1M Performance:
-3.32%
6M Performance:
-51.67%
1Y Performance:
-28.15%
1-Day Range:
$66.50
$68.27
1-Week Range:
$66.32
$70.00
52-Week Range:
$62.34
$142.00
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom (DXCM) Accused of Misleading Investors About Sales Force Changes and Financial Outlook- Hagens Berman - GlobeNewswire Inc.
Global Chronic Disease Management Market Size to Reach USD 17.28 Billion by 2033 | Witnessing a CAGR of 12.80% - GlobeNewswire Inc.
DEXCOM, INC. (NASDAQ: DXCM) DEADLINE ALERT: Bernstein - GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire
2 Magnificent Growth Stocks Down 45% and 32% to Buy Right Now - The Motley Fool
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2024 in DexCom, Inc. LawsuitDXCM - AccessWire
DXCM CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds InvestorsA Securities Fraud Class Action Lawsuit Has Been Filed Against DexCom, Inc. - PR Newswire
Faruqi & Faruqi Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024DXCM - PR Newswire
DXCM STOCK UPDATE: Investors of DexCom, Inc. are Alerted of Imminent October 21 Deadline; Contact BFA Law if You Lost Money (Nasdaq:DXCM) - GlobeNewswire Inc.
Legal & General Group Plc Purchases 49,076 Shares of DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
APG Asset Management N.V. Boosts Stake in DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Dexcom Inc [DXCM] Records 200-Day SMA of $112.31 - Knox Daily
Wall Street SWOT: DexCom stock faces headwinds amid CGM market expansion - Investing.com UK
DXCM FRAUD UPDATE: DexCom, Inc. Investors are Encouraged to Contact BFA Law before the Expiration of the October 21 Legal Deadline in Securities Fraud Case - AccessWire
ROSEN, A LONGSTANDING LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before - The Bakersfield Californian
Shareholders of DexCom, Inc. Should Contact Levi & Korsinsky Before October 21, 2024 to Discuss Your RightsDXCM - AccessWire
Shareholders That Lost Money on DexCom, Inc. (DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - AccessWire
DexCom, Stellantis, Symbotic, and NANO Nuclear Energy Class - GlobeNewswire
DexCom, Stellantis, Symbotic, and NANO Nuclear Energy Class Action Update: Johnson Fistel Alerts Shareholders of Ongoing Class Action Proceedings - GlobeNewswire Inc.
Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineDXCM - AccessWire
Levi & Korsinsky Reminds DexCom, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 21, 2024DXCM - AccessWire
DexCom (DXCM) Accused of Misleading Investors About Sales Force Changes and Financial Outlook – Hagens Berman - ForexTV.com
DexCom (DXCM) Accused of Misleading Investors About Sales Force Changes and Financial Outlook - The Bakersfield Californian
DexCom (DXCM) Accused of Misleading Investors About Sales Force Changes and Financial OutlookHagens Berman - GlobeNewswire
Class Action Filed Against DexCom, Inc. (DXCM) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Toronto Dominion Bank - MarketBeat
Dexcom Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024 at 4:30 p.m. Eastern Time. - BioSpace
Investors who lost money on DexCom, Inc.(DXCM) should contact Levi & Korsinsky about pending Class ActionDXCM - AccessWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom - Marketscreener.com
DXCM ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Kirby McInerney LLP Notifies Investors of Lead Plaintiff Deadline in Dexcom Inc. (DXCM) Securities Class Action - ForexTV.com
Kirby McInerney LLP Notifies Investors of Lead Plaintiff Deadline in Dexcom Inc. (DXCM) Securities Class Action - GlobeNewswire
Kirby McInerney LLP Notifies Investors of Lead Plaintiff Deadline in Dexcom Inc. (DXCM) Securities Class Action - GlobeNewswire Inc.
DexCom Inc. October 21, 2024 Lead Plaintiff Deadline – DXCM Investors Should Contact Robbins LLP for Information - GlobeNewswire
Stock Performance Spotlight: Dexcom Inc (DXCM) Ends the Day at 66.73, Down by -2.81 - The Dwinnex
Dexcom Inc [DXCM] Stock trading around $66.73 per share: What’s Next? - The DBT News
Dexcom Inc (DXCM) stock: A year of ups and downs - US Post News
Dexcom Schedules Third Quarter 2024 Earnings Release and Conference Call for October 24, 2024 at 4:30 p.m. Eastern Time. - Yahoo Finance
DXCM Stockholders Have Opportunity to Lead DexCom, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - AccessWire
APG Asset Management US Inc. Purchases 25,951 Shares of DexCom, Inc. (NASDAQ:DXCM) - MarketBeat
The Gross Law Firm Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 21, 2024 to Discuss Your Rights – DXCM - AccessWire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom - GlobeNewswire Inc.
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - Morningstar
Dexcom Inc Inc. (DXCM) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
2024-09-25 | DexCom, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationDXCM | NDAQ:DXCM | Press Release - Stockhouse Publishing
DXCM INVESTOR DEADLINE: If You Suffered Losses on Your DexCom, Inc. Investment, Contact BFA Law before October 21 Legal Deadline - Newsfile
Is DexCom a Millionaire Maker? - sharewise
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.46%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):